RxDoctor Payments Data

Debra Shapiro, MD

Internal Medicine · Cambridge, MANPI 1194775262

Payments from drug & device makers

$174in general payments, 2019–2025

Across 8 payments — averaging $21.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$42
  • Johnson & Johnson$31
  • AstraZeneca$30
  • Merck$27
  • Novo Nordisk$24
  • Sanofi Pasteur Inc.$21

What the payments were for

  • Food & beverage$174100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$174 in reported general payments places this provider in the 65th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$213,589
Medicare patients
335
Services billed
2,534

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban66$102,755
XareltoRivaroxaban34$48,473
JardianceEmpagliflozin32$37,517
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$37,011
OzempicSemaglutide19$24,510
Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df12$20,079
FarxigaDapagliflozin Propanediol13$16,831
MounjaroTirzepatide11$11,629
Combivent RespimatIpratropium/Albuterol Sulfate11$7,895
Atorvastatin Calcium424$7,096
Breo ElliptaFluticasone/Vilanterol16$6,938
Estradiol45$6,749
Metoprolol Succinate232$5,212
Rosuvastatin Calcium86$4,285
OxycontinOxycodone Hcl14$4,243

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$31$48,47334 claims
GSKTrelegy Ellipta, Breo Ellipta$42$43,94949 claims
Novo NordiskOzempic$24$24,51019 claims
AstraZenecaFarxiga$30$16,83113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Cambridge

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →